Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
The national capital has reported an ‘isolated’ case of Japanese Encephalitis (JE) in a 72-year-old…
The Central Drugs Standard Control Organisation found 56 drug samples tested in the central drug…
A team of doctors have removed a rare and complex black brain tumor from the…
Global pharma major Lupin Limited (Lupin) today announced its S&P Global ESG scores have moved…
Following a statement from Tata Memorial Centre, Dr. Abhishek Shankar, a senior oncologist from AIIMS…
Reacting to Navjot Singh Sidhu’s claim on wife’s cancer treatment and outcome, a group of oncologists…